Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
Affinity and Avidity01:41

Affinity and Avidity

38.4K
Overview
38.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-guided design of potent tetrazolo[1,5-a]pyrimidine-based tubulin inhibitors with in vivo antitumor activity.

European journal of medicinal chemistry·2025
Same author

Discovery of Novel 4,5-Dihydropyrrolo[3,4-<i>c</i>]pyrazol-6(<i>2H</i>)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.

Journal of medicinal chemistry·2025
Same author

Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer.

Journal of drug targeting·2024
Same author

Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.

European journal of medicinal chemistry·2024
Same author

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment.

European journal of medicinal chemistry·2024
Same author

Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy.

International journal of cancer·2024

Related Experiment Video

Updated: Jan 11, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.1K

Artificial intelligence in antibody-drug conjugate development.

Yuxi Wang1, Cuiyu Guo2, Weimin Li1

  • 1Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212, Sichuan, China.

Trends in Pharmacological Sciences
|November 11, 2025
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) is revolutionizing antibody-drug conjugate (ADC) development by enabling data-driven engineering. AI accelerates the design and optimization of ADCs for more effective cancer treatments.

Keywords:
antibody–drug conjugatesartificial intelligencedrug discoverymachine learning

More Related Videos

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
09:06

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

22.1K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

Related Experiment Videos

Last Updated: Jan 11, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.1K
Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
09:06

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

22.1K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

Area of Science:

  • Oncology
  • Biotechnology
  • Computational Biology

Background:

  • Antibody-drug conjugates (ADCs) are advanced therapeutics for targeted cancer treatment.
  • ADC development faces challenges including design complexity, toxicity, and variable clinical efficacy.
  • Optimizing ADCs requires precise matching of antibody, linker, and payload for stability and tumor-specific release.

Purpose of the Study:

  • To review the application of artificial intelligence (AI) in advancing antibody-drug conjugate (ADC) development.
  • To highlight how AI integrates diverse data for improved ADC design and clinical translation.
  • To outline future opportunities for AI-driven next-generation ADCs.

Main Methods:

  • AI models integrate antibody sequence, structural, and molecular dynamics (MD) features.
  • Data-driven approaches are shifting ADC development from empirical methods to closed-loop engineering.
  • Review synthesizes advances across preclinical and clinical ADC development phases.

Main Results:

  • AI accelerates key aspects of ADC development, including target selection and conjugate optimization.
  • AI models enhance the prediction of patient responses to ADC therapies.
  • AI facilitates a more rational and efficient approach to ADC design.

Conclusions:

  • AI is transforming ADC development into a data-driven, efficient process.
  • AI integration promises to overcome current limitations in ADC design and clinical application.
  • AI-enabled strategies are crucial for the future of next-generation antibody-drug conjugates.